Dr. Kolevzon serves as Clinical Director of Mount Sinai’s Seaver Autism Center and an Associate Professor at Icahn School of Medicine at Mount Sinai.
Dr. Kolevzon has published numerous papers on autism as well as three books designed for medical student and resident education. He has extensive clinical expertise in the psychopharmacology of autism and related conditions and his research is focused on developing new pharmacological treatments as an investigator on many clinical trials. He is also extremely committed to medical student and residency training and education and is the Associate Residency Training Director in Child and Adolescent Psychiatry at Mount Sinai. He is an active teacher, mentor, and clinical supervisor and has received many teaching awards as well as a grant to support innovative educational endeavors.
The Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai
Every effort has been made to ensure the accuracy of the information in this directory. However some
changes may occur between updates. Please check with your provider to ensure that he or she
participates in your health plan.
THURSDAY, May 23 (HealthDay News) -- Although a study in 2012 suggested a cancer drug could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now say they have been unable to duplicate those findings.
THURSDAY, May 23 (HealthDay News) -- The sensation of itching is hardwired into the nervous system and can be traced back to a small molecule released in the spinal cord, according to a new study in mice.
Researchers say this molecule, known as natriuretic polypeptide b (Nppb), triggers ...Full Article
WEDNESDAY, May 22 (HealthDay News) -- Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely -- a smaller brain.
Already aware that people with migraines face double the risk of dep...Full Article
WEDNESDAY, May 22 (HealthDay News) -- Over the next two decades, the cost of treating strokes in the United States is expected to more than double, topping more than $180 billion a year, according to new research.
The main factor driving the increase: an aging p...Full Article
Is there any new treatment in the pipeline for autism?
There are several new treatments in the pipeline for autism spectrum disorder. Curemark, LLC recently released positive results from a phase 3 clinical trial of their compound, Luminenz, that is focused on treating symptoms of hyperactivity in Autism. Seaside Therapeutics is also studying Arba...
All Content Posted on This Site is the Responsibility of the Party Posting Such Content. Participation on
This Site by a Party Does not Imply Endorsement of any Other Party’s Content, Products, or Services. Content
Should not be Used for Medical Advice, Diagnosis, or Treatment. see Additional Information.